Lund, Sweden, June 8, 2011 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is scheduled to present at the Jefferies 2011 Global Healthcare Conference held June 6-9, 2011 at the Grand Hyatt New York, New York City, US. During the presentation, an update regarding Active Biotech`s development programs will be provided.
The presentation will include projects in Phase III; laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ, in co-development with Ipsen as well as ANYARA, Active Biotech`s novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI project will be presented.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com.
The presentation will take place on June 8, at 2:00 pm US Eastern Daylight Time / 20.00 Central European Summer Time.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn`s and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDexTM for RA. Please visit www.activebiotech.com for more information.
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 08:30 am CEST on June 8, 2011.
Active Biotech AB
Göran Forsberg, VP Investor Relations & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00